BioDelivery Sciences International (BioDelivery Sciences International) Cash And Cash Equivalents : $114.3 Mil (As of Dec. 2021)

View and export this data going back to 2002. Start your Free Trial

What is BioDelivery Sciences International Cash And Cash Equivalents?

BioDelivery Sciences International's quarterly cash and cash equivalents declined from Jun. 2021 ($119.85 Mil) to Sep. 2021 ($100.71 Mil) but then increased from Sep. 2021 ($100.71 Mil) to Dec. 2021 ($114.31 Mil).

BioDelivery Sciences International's annual cash and cash equivalents increased from Dec. 2019 ($63.89 Mil) to Dec. 2020 ($111.58 Mil) and increased from Dec. 2020 ($111.58 Mil) to Dec. 2021 ($114.31 Mil).

BioDelivery Sciences International Cash And Cash Equivalents Historical Data

The historical data trend for BioDelivery Sciences International's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioDelivery Sciences International Cash And Cash Equivalents Chart

BioDelivery Sciences International Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Cash And Cash Equivalents

Get a 7-Day Free Trial

21.20

43.82

63.89

111.58

114.31

BioDelivery Sciences International Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Cash And Cash Equivalents	Get a 7-Day Free Trial															111.58	116.44	119.85	100.71	114.31

BioDelivery Sciences International Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

BioDelivery Sciences International (NAS:BDSI) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

BioDelivery Sciences International Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of BioDelivery Sciences International's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

BioDelivery Sciences International (BioDelivery Sciences International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioDelivery Sciences International Inc (NAS:BDSI) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

4131 ParkLake Avenue, Suite 225, Raleigh, NC, USA, 27612

Website

http://www.bdsi.com

BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.

Executives

James Vollins	officer: See Remarks	C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE SUITE 225, RALEIGH NC 27607
Mark A Sirgo	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Broadfin Healthcare Master Fund Ltd	director	C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Kevin Kotler	director	C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Mary Theresa Coelho	officer: See Remarks	52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Jeffrey Allen Bailey	director, officer: Chief Executive Officer	BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Todd C Davis	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
W. Mark Watson	director	324 S. HYDE PARK AVENUE, STE 350, TAMPA FL 33606
Peter Greenleaf	director	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Broadfin Capital, Llc	director	300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Vanila Singh	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Scott M. Plesha	officer: See Remarks	1410 SMYTHE ST DANIEL ISLAND SC 29492
Odonnell Francis E Jr	director	BIODELIVERY SCIENCES INTERNATIONAL, INC, 4131 PARKLAKE AVENUE, SUITE #225, RALEIGH NC 27612
Herm Cukier	director, officer: Chief Executive Officer	C/O BIODELIVERY SCIENTES INT., INC. 4131 PARKLAKE AVE, SUITE 225 RALEIGH NC 27612
Thomas B Smith	officer: Chief Medical Officer	BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612